Categories: News

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2022 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., July 25, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, August 10, 2022, at 3:00 p.m. Eastern Time, Shockwave Medical management is scheduled for a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference, which is taking place from Monday, August 8 – Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA.

Interested parties may access live and archived webcasts of these events on the “News & Events” section of the company’s investor website at https://ir.shockwavemedical.com.  

To access the live second quarter 2022 earnings call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com 

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com 

Staff

Recent Posts

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing…

7 hours ago

Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…

7 hours ago

Avinger Reports Fourth Quarter and Full Year 2023 Results

New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens…

7 hours ago

Music’s Healing Influence on Our Physiology

Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20,…

10 hours ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or…

10 hours ago

Mending Kids’ Imagine Gala Triumphs, Elevating Children’s Surgical Care Initiatives

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Skirball Cultural Center was…

10 hours ago